A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus

Simply Wall St.06-05 05:34

Agilent Technologies (A) stock is back in focus after a packed stretch of news, including expanded FDA approval for its PD-L1 diagnostic, a new artificial intelligence collaboration with OpenAI and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641716069?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530","is_english":true,"pubTime":"2026-06-05 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641716069","market":"nz","top_or_hot":-1,"title":"A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus","media":"Simply Wall St.","content":"<div>\n<p>Agilent Technologies (A) stock is back in focus after a packed stretch of news, including expanded FDA approval for its PD-L1 diagnostic, a new artificial intelligence collaboration with OpenAI and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/a-look-at-agilent-technologies-a-valuation-as-fda-approval-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 05:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/a-look-at-agilent-technologies-a-valuation-as-fda-approval-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agilent Technologies (A) stock is back in focus after a packed stretch of news, including expanded FDA approval for its PD-L1 diagnostic, a new artificial intelligence collaboration with OpenAI and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/a-look-at-agilent-technologies-a-valuation-as-fda-approval-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIX","symbol_name":"通用人工智能 ETF-AGIX","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/a-look-at-agilent-technologies-a-valuation-as-fda-approval-a","article_id":"2641716069","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/a-look-at-agilent-technologies-a-valuation-as-fda-approval-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641716069","pubTimestamp":1780608855,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Agilent Technologies (A) stock is back in focus after a packed stretch of news, including expanded FDA approval for its PD-L1 diagnostic, a new artificial intelligence collaboration with OpenAI and Boston Consulting Group, and stronger than expected quarterly results with raised guidance.\nSee our latest analysis for Agilent Technologies.\nThe recent AI collaboration and product launches have coincided with a 17.73% 1 month share price return and a 20.25% 3 month share price return. The 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AGIX":"通用人工智能 ETF-AGIX","ARTY":"ISHARES FUTURE AI & TECH ETF","LABU":"三倍做多标普生物-Direxion","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AIPO":"Defiance AI and Power Infrastructure ETF","A":"安捷伦科技"},"translate_title":"随着FDA批准人工智能交易和盈利更新引起关注，安捷伦科技(A)的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":1.5,"AIPO":1.5,"ARTY":1.5,"LABU":1.5,"CHAT":1.5,"A":1.5},"content_text":"Agilent Technologies (A) stock is back in focus after a packed stretch of news, including expanded FDA approval for its PD-L1 diagnostic, a new artificial intelligence collaboration with OpenAI and Boston Consulting Group, and stronger than expected quarterly results with raised guidance. See our latest analysis for Agilent Technologies. The recent AI collaboration and product launches have coincided with a 17.73% 1 month share price return and a 20.25% 3 month share price return. The 1 year total shareholder return of 22.44% points to momentum building over a longer horizon. If you are watching how AI and digital workflows shape the next wave of lab tools, it may be worth scanning other opportunities through our screener for 61 profitable AI stocks that aren't just burning cash Agilent now trades at $138.37, with an intrinsic value estimate implying roughly a 20% discount and a 16% gap to the average analyst target. So are you looking at an underappreciated compounder, or a stock already pricing in future growth? AdvertisementMost Popular Narrative: 14.1% Undervalued At $138.37, the most followed narrative pegs Agilent Technologies’ fair value at about $161, which points to a meaningful gap for investors to weigh.  Strategic investments in higher-margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.  Read the complete narrative. Want to see what sits behind that valuation gap? The narrative leans heavily on compounding revenue, rising margins, and a richer earnings mix over time. Result: Fair Value of $161.07 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are real pressure points to watch, including tariff related cost headwinds and any prolonged slowdown in government or academic lab funding that could weaken demand. Find out about the key risks to this Agilent Technologies narrative. Next Steps Does this all sound optimistic or cautious to you? Take a moment to review the data points, pressure tests, and valuation gaps yourself, then weigh the 3 key rewards Looking for more investment ideas? Do not stop with just one stock. Use powerful screens to spot fresh ideas so you are not looking back later wishing you had started sooner.  Target potential mispricing by scanning the market for companies flagged in our value focused list through 46 high quality undervalued stocks Prioritise financial strength by filtering for opportunities highlighted in the solid balance sheet and fundamentals stocks screener (47 results) Unearth earlier stage opportunities by reviewing the 24 elite penny stocks with strong financials   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641716069","isCrawlerRequest":true}